Di Minno et al. reported that increased BMI predicted less favorable response to TNFα blockers in patients with PsA who were followed for 24 months (106); and Eder et al. found that overweight and obesity are associated with a lower probability of achieving MDA among patients with PsA, independently of the use of biological and non-biological DMARDs (107). Here, TNF is linked to Obesity.